Pharmaceutical ingredients manufacturer will end operations at the Riverside site next year, launching three rounds of job cuts.<\/p>\n\n\n\n
Merck<\/strong> has officially revealed that it will shut down its pharmaceuticals plant in Riverside, Pennsylvania<\/strong>, with 163 employees<\/strong> expected to lose their positions. The company\u2019s statement indicates that the first two rounds of layoffs<\/strong> are scheduled between May 16 and May 30<\/strong>, and from June 23 to July 7<\/strong>, followed by a final round in 2026<\/strong>.<\/p>\n\n\n\n Company representatives clarified that the plant\u2019s performance was not a factor in deciding to close the facility. Instead, Merck<\/strong> pointed to ongoing assessments of its operations and business needs. Did you know that this closure was initially hinted at in 2022<\/strong>? At that time, around 300 workers<\/strong> were employed at the Riverside<\/strong> location, which was set to cease production of active pharmaceutical ingredients<\/strong> in 2024<\/strong>.<\/p>\n\n\n\n According to a Pennsylvania Worker Adjustment and Retraining Notification<\/strong>, the first set of layoffs<\/strong> will occur by May 30<\/strong>, followed by another wave in late June<\/strong>. A final phase will come in 2026<\/strong>, effectively concluding the site\u2019s activities. Merck<\/strong> has underscored its commitment to supporting impacted workers throughout the transition, offering severance packages<\/strong> to those affected by this decision.<\/p>\n\n\n\n Below is a quick overview of the announced schedule:<\/p>\n\n\n\n Merck<\/strong> operates multiple manufacturing facilities across the United States in states like Iowa, Kansas, Minnesota, Delaware, North Carolina, Virginia<\/strong>, and Nebraska<\/strong>. Recently, it opened a $1 billion vaccine manufacturing site<\/strong> in Durham, North Carolina<\/strong>, signaling a broader expansion in certain regions despite the planned closure in Pennsylvania<\/strong>.<\/p>\n\n\n\n The Riverside<\/strong> plant has also faced environmental challenges over the years. Groundwater contamination<\/strong> resulted in cleanup measures initiated by Merck<\/strong>, with the remediation system<\/strong> still in place. Prior to Merck\u2019s<\/strong> tenure, the facility was leased by Heyden Chemical Company<\/strong> during World War II<\/strong> for munitions production.<\/p>\n\n\n\n Curious about how this might affect the local economy? In fact, Merck<\/strong> has invested more than $3 billion<\/strong> in its Pennsylvania<\/strong> operations, employing roughly 14,000 people<\/strong> statewide. While the closure is significant, the company maintains it remains committed to the region.<\/p>\n\n\n\n Here is a brief list of Merck\u2019s<\/strong> notable locations in the United States, aside from Pennsylvania<\/strong>:<\/p>\n\n\n\nKey details about the staggered layoffs and why they are happening now<\/h2>\n\n\n\n
Layoff Round<\/th> Approximate Dates<\/th> Number of Affected Employees<\/th><\/tr><\/thead> First<\/td> May 16 – May 30, 2023<\/td> Not specified<\/td><\/tr> Second<\/td> June 23 – July 7, 2023<\/td> Not specified<\/td><\/tr> Final<\/td> 2026<\/td> Part of the total 163<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n Further implications for Merck\u2019s employees and Pennsylvania\u2019s broader pharmaceutical sector<\/h2>\n\n\n\n